Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP.
The cardiovascular consequences of endothelin (ET) blockade with the ETA receptor antagonist FR 139317 were evaluated by determining long-term effects of the drug on hemodynamic, hormonal, and structural parameters in stroke-prone spontaneously hypertensive rats (SHR-SP). Young SHR-SP on a high-sodium diet develop malignant hypertension accompanied by renovascular and cerebrovascular lesions. In control SHR-SPs the systolic blood pressure increased from 196 +/- 3 to 260 +/- 4 mm Hg, whereas in animals treated with FR 139317 (20 mg/kg, i.p., b.i.d.) blood pressure increased only from 196 +/- 4 to 212 +/- 3 mm Hg during a treatment period of 6 weeks. The increase in heart weight was also delayed. At the end of the experiment, the plasma levels of ANP and BNP were significantly lower in the group treated with FR 139317 than in the controls. The plasma ET levels were significantly higher and the plasma renin activity was lower in the group treated with the ET receptor antagonist. These data indicate that ET is involved in the maintenance of high blood pressure and cardiac hypertrophy in malignant hypertension, as exemplified by an SHR-SP rat model.
Stasch
J P
JP
Bayer AG, Pharma Research Center, Wuppertal, Germany.
Hirth-Dietrich
C
C
Frobel
K
K
Wegner
M
M
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D001381:Azepines / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000209:etiology / Q000517:prevention & control*; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000097:blood / Q000502:physiology; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control*; D007211:Indoles / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D044022:Receptor, Endothelin A
D001381:Azepines; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D007211:Indoles; D044022:Receptor, Endothelin A; C079574:FR 139317; D009320:Atrial Natriuretic Factor